Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Deirdre Coleman
"Mary Shelley" shows the young "Frankenstein" author through the lens of #MeToo
The lives of young Romantic artists continue to fascinate filmmakers, from Ken Russell’s Gothic (1986) about Lord Byron, to Jane Campion’s Bright Star (2009) about John Keats. With the 200th anniversary of Frankenstein upon us, a new film, Mary Shelley, focuses on its author. Frankenstein was conceived by the 18-year-old Mary Shelley while she was with her stepsister Claire Clairmont, the poets Lord Byron and Percy Bysshe Shelley, and Byron’s physician John Polidori.
The film, Mary Shelley, shows Frankenstein is always a story for our times
The lives of young Romantic artists continue to fascinate filmmakers, from Ken Russell’s Gothic (1986) about Lord Byron, to Jane Campion’s Bright Star (2009) about John Keats. With the 200th anniversary of Frankenstein upon us, a new film focuses on its author, Mary Shelley. Frankenstein was conceived by the 18-year old Mary Shelley while she was with her stepsister Claire Clairmont, the poets Lord Byron and Percy Bysshe Shelley, and Byron’s physician John Polidori.
The film, Mary Shelley, shows Frankenstein is always a story for our times
The lives of young Romantic artists continue to fascinate filmmakers, from Ken Russell’s Gothic (1986) about Lord Byron, to Jane Campion’s Bright Star (2009) about John Keats. With the 200th anniversary of Frankenstein upon us, a new film focuses on its author, Mary Shelley. Frankenstein was conceived by the 18-year old Mary Shelley while she was with her stepsister Claire Clairmont, the poets Lord Byron and Percy Bysshe Shelley, and Byron’s physician John Polidori.
The call for a more strategic medical affairs community
How its leaders are stepping up to the plate Shifting demands are causing Medical Affairs to broaden its remit, transforming the function from what was traditionally a supportive role into a strategic decision-maker and trusted scientific partner.
Cementing the Value of Medical Affairs
A number of trends including tougher regulatory controls, increased transparency expectations, an increasingly vocal patient and greater requirements for post-marketing evidence have driven the growth of medical affairs over the years.
Digital health
Digital health is projected to be worth $230bn by 2020. Investments in digital solutions and services skyrocketed during 2017, across the spectrum of telemedicine, wearable technology, mobile applications and remote monitoring sensors, with offerings designed to help healthcare professionals and patients prevent and manage illnesses and health risks, and also to promote well-being.
GSK’s Bid To Accelerate Drug Discovery Using AI
GSK’s goal is to transform drug discovery from a slow, sequential, high-failure process into a rapid, integrated, and patient-focused model with the help of tools like artificial intelligence and data. We spoke to Mark Ramsey, chief data officer for R&D (CDO) at GSK, who leads the development and execution of the data strategy for R&D. The goal of the data strategy is to allow GSK to execute clinical trials more effectively and efficiently, and to accelerate drug discovery.
5 Leadership Questions For Camilla Harder Hartvig
Camilla Harder Hartvig is SVP of Canada and EMEA for Alexion Pharmaceuticals. Previously she was president, Europe and emerging markets, at Glenmark Pharmaceuticals and also worked for companies such as Allergan, AstraZeneca, and Novartis in various managerial positions. THIS CONTENT IS EXCLUSIVELY FOR LIFE SCIENCE LEADER PAID SUBSCRIBERS.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
Marc Princen is invigorated by what he does best – building and transforming businesses Marc Princen’s three-decade career is defined by two words – building and transforming. Now Executive VP and President of International Business at Allergan, he got his first taste of both as General Manager in Turkey at Schering-Plough when he was only 32. “It was very fortunate for me as I got exposure to building up a business in new markets and new regions,” he says.
Active Partners in Research
GSK are tapping into their consumer division's skill of capturing consumer insights - could FMCI (Fast-Moving Consumer Insights) be the way forward? As companies increasingly integrate patient input into their R&D activities, they are realizing that they must also forge strong partnerships with patients and their families. Yet, how do you transform buzzwords like patient engagement, patient voices, patient partnerships from theory into practice?
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
ICER has the laudable mission of being an independent, trusted source of value assessment for medicines. We spoke to Chief Scientific Officer, Dan Olldendorf, about controversy, criticism and the power of collaboration. As Chief Scientific Officer at ICER, Dan Ollendorf has the perhaps unenviable task of supporting all of ICER’s stakeholders in discussions around the value of new drugs.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
How do we optimize medical affairs to engage patients, understand their needs and create patient-centric medical information exchange The evolution of Medical Affairs from focusing on educating HCPs on the science behind medicines to an integrated business unit building two-way relationships with multiple stakeholders has been rapid. Within this much broader remit, a key challenge is funnelling patient insights into company decision making.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
Pharma may be missing an opportunity by not involving Medical Affairs in early stage development There is a consensus within the industry that Medical Affairs (MA) has an opportunity to redefine its role but there are still questions to be answered about the structure and shape of the new optimized MA department.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
How can we be truly patient-centric if our companies aren’t representative of the richness of human experience? Whether understanding a patient pathway, designing a service platform or training staff, patient centricity is, at its core, about the continued desire to improve the patient experience. This requires an understanding of the patient experience for everyone, regardless of gender, sexual orientation, race, religious beliefs, disability, socio-economic background or age.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
To achieve career success, we need to get our inner and outer worlds in sync To propel our careers forward, we’re told we must ‘lean in’, enduring short-term pain for long-term gain, but, what if we’ve got it backwards? What if the pursuit of happiness – and that elusive word ‘balance’ – is vital to career success, rather than the other way around?
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
Maximizing reimbursement in a challenging pricing environment requires market access and pricing teams to work in concert As private and government payers around the world grow more powerful, obtaining market access promptly at an appropriate price has become critical to company success. Faced with a raft of challenges, including the advent of lower-priced generics and biosimilars, branded biologics manufacturers are finding it increasingly difficult to command premium prices.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
Numerous barriers impede the full realization of benefit from Real World Evidence RWE and patient outcomes are becoming a powerful currency for engagement and demonstrating product value. However, numerous barriers impede the full realization of benefit from RWE. What are the key challenges around data access and governance and what capabilities will be required to deliver on the potential of RWE? Cost pressures and the need to demonstrate that drugs add promised value is higher than ever.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
Pharma’s engine of growth lies firmly within Medical Affairs and its ability to partner effectively with other functions. The star of Medical Affairs (MA) is rising fast, placed under a spotlight by the urgent need of pharmaceutical companies to prove the value of their medicines. Yet, MA has also earned its place at center stage, embracing technology and innovation to enable it to inform strategy and drive influence across the entire organization as well as the healthcare ecosystem.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
The age of consumer empowerment is in full force and the industry must respond and adapt to customer engagements. In a landscape where no single healthcare journey is identical, the emerging mandate for pharma is to develop, orchestrate and optimize an ever-agile, adaptive customer engagement strategy. One key challenge to the delivery of an effective customer engagement experience rests in the alignment and communication of insight from field teams.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
According to Takeda's Thy Do, the secret lies in changing our mindset towards clinical trials. “Rather than asking ‘Will this treatment work in the real world?’ we ask ‘Does this treatment work in a well-defined population?’. Pragmatic trials involve a complete change in mindset; the traditional clinical trialist thinking about stringent enrollment criteria is trying to homogenize the patient population and shift the population into a higher risk area so it’s easier to see a treatment effect.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
Part 1 of a 2 part series: Unlock valuable insights throughout the lifecycle Pharma is undergoing an ‘evidence revolution’ as real-world evidence breaks out from the confines of market access and infiltrates every part of the life of a medicine, from discovery through to late-stage commercial.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
As Senior Medical Officer at the European Medicines Agency (EMA), Dr Hans-Georg Eichler has the unenviable double task of being a guardian of public safety and an enabler of innovation. As such, he is at the forefront of industry-transforming trends around the gathering and interpretation of real-world evidence. “There will always be far more questions in a conventional drug development program with randomized control trials than we can answer,” he says.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
Medical Science Liasions need more than just scientific acumen to get the message across. There has been an explosion in the number of Medical Science Liaisons (MSLs) over the last few years, spurred by the trends that can be best summed up as the shift from volume to value. Companies want partnerships with customers through peer-to-peer interactions that deliver customer value and scientific credibility.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
Dr Ameet Nathwani, Chief Medical Officer at Sanofi, discusses the vital role Medical Affairs is playing in using data to demonstrate value Proving the effectiveness of a medicine used to be a ‘simple’ case of getting great efficacy data from phase III clinical trials. But the world has changed, as payers demand companies demonstrate the value of their drugs.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
MA is set to become a fully-fledged strategic partner. But what has driven this change & what can we expect in years to come? The remarkable surge in the size and importance of the Medical Affairs function within pharma companies has roots going back decades. Over many years, pressure from regulatory agencies, payers and healthcare professionals, as well as public sentiment, has led to a clearer separation between the Medical and Commercial functions.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
MA is set to become a fully-fledged strategic partner. But what has driven this change & what can we expect in years to come? The remarkable surge in the size and importance of the Medical Affairs function within pharma companies has roots going back decades. Over many years, pressure from regulatory agencies, payers and healthcare professionals, as well as public sentiment, has led to a clearer separation between the Medical and Commercial functions.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
Tim Walbert, CEO, Horizon Pharma, explains how doing right by the patient can still lead to significant profits. Tim Walbert helped to launch two of the world’s biggest-selling drugs, Humira and Celebrex, and is now in charge of a $3 billion company with big ambitions – plus he knows what it is like to be a patient at the sharp end. That is quite a track record.
Thought leadership and innovation for the Pharmaceutical Industry - EyeforPharma
We asked these pharma leaders at eyeforpharma Barcelona what they loved about their jobs. Here's what they had to say. “The key challenge for business is how do we get more purpose-driven leaders that realize they are there to make a difference in the world”, said Bill George of Harvard Business School at The World Economic Forum, which took place in Davos. “The pressures are greater today than they’ve ever been on CEOs to produce short-term results but it’s really not about that.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Deirdre
Contact Deirdre, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack